Neurocrine Biosciences

NAS:NBIX

Biotechnology

Market Cap

$7.17bn

MID cap

Share Price ↑

$78.91 (2.07%)

YTD Return ↑

12.5838%

since start of 2019

P/E Ratio

464.18

NBIX chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

About

Biotechnology Founded 1992

Neurocrine Biosciences, Inc. operates as a product based biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale on January, 1992 and is headquartered in San Diego, CA.

website

Source: FactSet Research Systems

Headquarters

12780 El Camino Real

San Diego, CA 92130

1.858.617.7600

Executives

Name	Title	Gender
Errol B. de Souza, PhD	Founder	Male
Kevin Charles Gorman, PhD, MBA	Chief Executive Officer & Director	Male
Christopher Flint O'Brien, MD	Chief Medical Officer	Male
Darin M. Lippoldt	Chief Legal Officer	Male
William H. Rastetter, PhD	Chairman	Male
Paul W. Hawran, CPA	Founder	Male
Wylie W. Vale, PhD	Founder	Male
Dimitri E. Grigoriadis, PhD	Chief Research Officer	Male
Bill Wilson	Vice President-Information Technology & Operations	Male
Malcolm Lloyd-Smith	Chief Regulatory Officer	Male
Jane Sorensen	Head-Investor Relations	Female
David-Alexandre C. Gros, MD, MBA	President, Chief Operating & Financial Officer	Male

Mindful Investing Summary

Legend

Carbon Footprint — N/A

Neurocrine Biosciences among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention — N/A

Neurocrine Biosciences on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation — N/A

Neurocrine Biosciences among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection — N/A

Neurocrine Biosciences among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety — N/A

Neurocrine Biosciences compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay — N/A

Neurocrine Biosciences among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety — N/A

Neurocrine Biosciences among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance — N/A

Neurocrine Biosciences among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices — N/A

Neurocrine Biosciences compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials — N/A

Neurocrine Biosciences among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor — N/A

Neurocrine Biosciences compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership 2 N/A

Neurocrine Biosciences performs poorly based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

Neurocrine Biosciences - Competitors and Related Companies

How Neurocrine Biosciences stacks up to its peers in the Biotechnology industry or with competing business segments.